Details for Patent: 8,754,109
✉ Email this page to a colleague
Title: | Pirfenidone therapy and inducers of cytochrome P450 |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. |
Inventor(s): | Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Filing Date: | Dec 03, 2010 |
Application Number: | 13/513,472 |
Claims: | 1. A method of increasing the effectiveness of pirfenidone therapy by avoiding decreased exposure to pirfenidone, in a patient in need of pirfenidone therapy and taking a strong inducer of cytochrome P450 1A2 (CYP1A2), comprising administering to the patient a therapeutically effective amount of pirfenidone, and avoiding the strong inducer of a cytochrome P450 1A2 (CYP1A2). 2. The method of claim 1, wherein the patient has idiopathic pulmonary fibrosis. 3. The method of claim 1, wherein the patient suffers from a fibrosis condition. 4. The method of claim 1, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg. 5. The method of claim 2, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg. 6. The method of claim 1, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg. 7. The method of claim 2, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg. 8. The method of claim 1, wherein each dose of pirfenidone administered is 801 mg. 9. The method of claim 6, wherein pirfenidone is administered three times a day. 10. The method of claim 9, wherein pirfenidone is administered with food. 11. The method of claim 1, wherein the strong CYP1A2 inducer is cigarette smoke. 12. The method of claim 11, wherein the patient has idiopathic pulmonary fibrosis. 13. The method of claim 11, wherein the patient suffers from a fibrosis condition. 14. The method of claim 11, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg. 15. The method of claim 12, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg. 16. The method of claim 11, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg. 17. The method of claim 12, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg. 18. The method of claim 16, wherein pirfenidone is administered three times a day. 19. The method of claim 18, wherein pirfenidone is administered with food. |